Literature DB >> 20601805

Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.

Manasi M Shah1, Mumhammad Wasif Saif.   

Abstract

Although pancreatic cancer is recognized as a major risk factor for venous thromboembolism, the exact magnitude of the problem is not known. The incidence varies from 17% to 57% depending on different studies. The effect of venous thromboembolism on outcomes in not well defined and there is no known independent predictor of survival. This review is an update from the current American Society of Clinical Oncology (ASCO) Annual Meeting regarding the impact of thrombotic events on the clinical outcomes, the association of tissue factor and thrombotic events, and the primary prevention of venous thromboembolism in pancreatic cancer patients undergoing active treatment.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20601805

Source DB:  PubMed          Journal:  JOP        ISSN： 1590-8577


  8 in total

1.  Letter to the Editor re: "Outcome analysis in 3160 implantations of radiologically guided placements of totally implantable central venous port systems": observations about right internal jugular access.

Authors:  Pierre-Yves Marcy; Alexis Lacout; Andrea Figl; Juliette Thariat
Journal:  Eur Radiol       Date:  2011-05-28       Impact factor: 5.315

Review 2.  Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes.

Authors:  Attila Zalatnai; Eszter Perjési; Eszter Galambos
Journal:  Pathol Oncol Res       Date:  2017-02-03       Impact factor: 3.201

Review 3.  Anticoagulation in the management of venous thromboembolism in the cancer patient.

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

4.  Distant Thromboembolic Disease Diagnosed by Endoscopic Ultrasound in Pancreatic Cancer: A Case Series.

Authors:  Catarina Atalaia-Martins; Pedro Pinto-Marques; Irina Mocanu; João Cortêz-Pinto; David Serra
Journal:  GE Port J Gastroenterol       Date:  2018-03-06

5.  Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.

Authors:  Jeffrey R Infante; Hendrik-Tobias Arkenau; Johanna C Bendell; Mark S Rubin; David Waterhouse; George Tripp Jones; David R Spigel; Cassie M Lane; John D Hainsworth; Howard A Burris
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

6.  New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions.

Authors:  Susanne Klein-Scory; Mahnaz Moradian Tehrani; Christina Eilert-Micus; Kamila A Adamczyk; Nathalie Wojtalewicz; Martina Schnölzer; Stephan A Hahn; Wolff Schmiegel; Irmgard Schwarte-Waldhoff
Journal:  Proteome Sci       Date:  2014-11-18       Impact factor: 2.480

7.  Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood Samples.

Authors:  Ruoxiang Wang; Nicholas N Nissen; Yi Zhang; Chen Shao; Chia-Yi Chu; Carissa Huynh; Edwin M Posadas; James S Tomlinson; Michael S Lewis; Stephen J Pandol
Journal:  Front Physiol       Date:  2022-02-14       Impact factor: 4.566

8.  The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis.

Authors:  Hussein Echrish; Leigh A Madden; John Greenman; Anthony Maraveyas
Journal:  Cancers (Basel)       Date:  2011-01-11       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.